Connect with us

Entrepreneur

“We are terrified to say the word ‘vagina'”- the founder educating the world on reproductive health

After years of being ignored and dismissed, Golnoush Golshirazi was diagnosed with endometriosis

Published

on

Dr Golnoush Golshirazi, co-founder and CEO of ScreenMe

Vaginal health is an essential part of a woman’s overall health. Yet, misconceptions surrounding this topic often lead individuals to feel dirty or ashamed when experiencing problems.

The lack of research into vaginal health and women’s health more generally seems only to perpetuate these misunderstandings, leaving women suffering in silence.

Dr Golnoush Golshirazi knows this too well. After years of being ignored and dismissed by healthcare professionals, she was diagnosed with endometriosis.

Wanting to make a change, the now researcher and women’s health advocate built her own business and launched ScreenMe, a platform that screens for every bacteria present in the vaginal microbiome and helps women better understand their reproductive health. She sat down with us to share her story.

Hi Golnoush, could you tell us a bit more about your background?

My background is molecular biology, with a PhD in genetics.

What inspired you to create ScreenMe?

My own personal health journey was what really ignited my passion to help others in the health space. It took thousands of pounds and many years until I got my endometriosis diagnosis. I felt constantly dismissed, ignored by professionals and unable to perform at my very best.

I always remember getting my period during one of my final exams for my university degree. I literally couldn’t move from my bed, and after ringing up, the invigilators were able to bring me my exam paper at least – however, the fact that I had to sit an exam when all I could think about was the huge pain I was experiencing (and be supposed to feel ‘grateful’ for this), is something that I will always remember.

After receiving my endometriosis diagnosis, I took a look back at this long and painful journey and vowed that I wanted to work to make sure this changed for others.

I saw that I could really use my own knowledge and expertise to advance healthcare responses and assist in creating solutions that genuinely worked for people. It wasn’t just this, but the wish to create a space where people felt heard and had access to the science that can really change their life – as this was something I struggled to find and wish I had looking back.

How would you describe ScreenMe in a few words?

Wow, that is a hard one. In just a few words I would say: answers and solutions, with care. This is because ScreenMe brings cutting-edge science to those who need it, but also pairs such with professional guidance, education and genuine support, to create solutions that work for you as an individual.

What makes ScreenMe different?

ScreenMe’s main difference I would say comes from making cutting-edge science accessible to the general public and bringing together the scientific, medical and holistic field for support.

As a team of scientists, medical professionals and holistic practitioners, and experts within the women’s health space we have decades of experience between us. This allows us to separate fact from fiction and really give advice and solutions that work for our community.

In a world which is moving towards a preventative and holistic care model – our team is so passionate about this and works towards such every day. Our team is also why we focus on education and awareness. We are aware from our own experiences that so many people know so little about intimate health and its long-term implications for fertility, infection, and disease – so it is our team who have focused our strategy on first educating society on the topic.

Then people can make informed, evidenced decisions as to what care, testing or support they need (if at all). We are passionate about not trying to push the ‘hard-sell’ on our product, but empower people with the agency to make the decisions that are right for them.

In terms of technicalities. ScreenMe is the only UK-based company that provides NGS-based screening of vaginal and seminal samples for bacteria and yeast allowing identification of all species present at very high accuracy.

Do you feel there is a lack of awareness around the importance of the vaginal microbiome and vaginal health in general?

As a society we are terrified to even say the word ‘vagina’, let alone open up discussions around this or provide adequate education. Most people do not even know the difference between the vulva and the vagina; or do not know that there are actually seven holes in their intimate area (most think there are three!).

So many of the people with vaginas we see each day have no clue about the implications of the symptoms they have been experiencing, or even the basics on how to look after their intimate health. This lack of awareness also extends out into the medical community.

Vaginal ecosystem and the role of the vagina in the bigger picture of health is hardly spoken about at med school. So many concerns could be prevented or resolved if people only had access to the correct information and services – so this is honestly something that I could speak about all day.

Such a severe lack of education is why we include a free one-to-one consultation with a practitioner for each of our tests, so that results can be explained and solutions can be curated.

This is also why we have published our free online Vaginal Health Clinic on our site where we provide the latest information regarding the vaginal microbiome and how this relates to a whole host of concerns, including recurrent infection, miscarriage, IVF success, thrush, cancer risk and much more.

How do you think we could start educating people on these subjects?

For me, the two most important ways to do this is through schools and educating the healthcare system itself.

Firstly, regarding schools, it is simply not enough to learn about the reproductive organs and their very basic functions. We need to ensure that there is effective and detailed education for all genders on the many layers of health, which includes intimate health, the role of hormones, menstrual conditions and disorders, sexual health and wellbeing, menopause, fertility complications, and so much more.

Schools are such a brilliant access point to allow people to understand from an early age, how to look after themselves, how to protect their health, what symptoms to look for, and also how to interact and understand others who may be suffering from particular health concerns or conditions.

We also are really passionate about educating the healthcare community about this topic. You would be amazed at how little is often required to be learnt about intimate health and so we do a lot of work with practitioners to improve their knowledge on this topic – including webinars and broadcasts.

Vaginal health often comes with a lot of stigma. How did you find establishing your business in this sector?

We actually started focusing on women’s health care in general and it was only through listening to our community that we realised what a huge gap there was in understanding, testing, services and support for intimate health. So, while there have been barriers in this pivot, we ultimately have had a core community who are so appreciative of the work we do for them and want to hear more about vaginal health.

I think reading the many positive reviews that state how we have changed people’s lives, really keeps us motivated. However, having a business in this sector has been difficult when approaching investors.

Intimate health is not always something that people are comfortable speaking about, so it is sometimes difficult to present appropriate data on such, or have productive conversations. Yet this is something we are striving to change every day!

What obstacles have you encountered on this journey?

I guess the main obstacle I have faced is actually being a woman. We hear all the time how gender disparities reveal themselves in the workplace and in society as a whole – but I guess you never really realise the extent of this until you experience them first-hand yourself.

Particularly when looking for investment, it is difficult to always communicate some of the many struggles that women face daily, and present them as a consumer market – despite women making the majority of household health-related spending decisions!

I have even been in a room myself with an investor and my co-founder (who is a man), and the investor asked me for a tea and assumed that I was the assistant. It was only when we started the meeting and my co-founder asked me to answer the first question, that the investor realised the mistake he had made. Of course, instances like this do serve well to light a fire in my belly, but it is unrealistic to say that they aren’t sometimes difficult to navigate.

Where are you with ScreenMe now?

We are currently really focusing on our expansion of intimate health services. This has a multi-pronged approach including: providing top-quality thought leadership, providing our services globally and expanding the network with whom we work with.

Each month we are receiving more attention and onboarding more partners, practitioners, clinics and customers. We want to expand out outreach and awareness, so that intimate health is something everyone understands and makes a part of their routine check-ups. As we build momentum, we are so excited to see this future starting to take shape in front of us, even if there is still a way to go yet.

We have also recently launched our semen microbiome testing service. This is so we can help everyone with their intimate health. The semen microbiome is also really important for a range of similar reasons, including fertility, IVF success, infection risk, and risk of disease.

Further, in the case of heterosexual partners, this allows us to treat couples as a pair and prevent reinfections – as there is no use for only one person to do all of the work to optimise intimate health, when their sexual partner is doing nothing!

What are you looking to achieve with ScreenMe?

We want to achieve a world in which intimate and reproductive health is a key feature of education and research and people are able to get the testing, support and services required to improve such. It is crazy to me that we are still using swab culture methods to investigate intimate health, when this was a method devised over 100 years ago.

NGS is an available technology which provides much greater accuracy and is able to screen 100 per cent of the bacteria present, rather than a selected panel of pre-selected bacteria as used in swab culture or PCR methods.

ScreenMe works to make this technology available to everyone, so that they can understand the full context of their microbiome, rather than just get a few pieces of the puzzle. So, really what we are working towards is empowering everyone with their intimate health and at the same time seriously powering up research which is crucial for better intimate and reproductive health.

Where do you see the company in the future?

I see ScreenMe as the go-to platform for people globally when it comes to their intimate and reproductive health. I see a trustworthy, science-based place where men and women find answers, solutions, support and education with all of this leading to lower risk of non-communicable diseases across society.

I have big ambitions, so I don’t just want to see ScreenMe changing and growing in the future, but I want to see the whole of intimate health as we know it changing due to ScreenMe’s work!

Dr Golnoush Golshirazi is the co-founder and CEO of ScreenMe. She is a Cambridge graduate, scientist and entrepreneur who advocates for women’s equality within the healthcare system. 

Entrepreneur

Last chance to save on Women’s Health Week and Women’s Sport Summit: Early Bird pricing ends 11 September

Published

on

Early bird pricing for W Group’s two flagship October summits – Women’s Health Week Europe 2026 and Women’s Sport Summit Europe 2026 – closes on 11 September.

Both events take place at Emirates Stadium, London, bringing together founders, investors, corporates, and industry leaders shaping the future of women’s health and sport.

Women’s Health Week Europe 2026

7-8 October | Emirates Stadium, London

This year’s edition will be Women’s Health Week Europe biggest one yet: with 700+ attendees, 80+ speakers, and 20+ sponsors, it will also feature two stages – a Global Stage covering market trends and policy, and a Scale Stage focused on company-level growth and commercialisation. WHW takes place across two days of content, business matchmaking, and dealmaking.

Agenda highlights include:

  • Where Capital Flows: Funding Trends in Women’s Health – with Merete Clausen (EIF), Ekaterina Gianelli (Calm/Storm), Henriette Hessen (Verdane), Jemma Day (British Business Bank), Ravit Warsha Dor (Telus Global Ventures), Tim Davis (LSEG)
  • Six Feet Under-funded: Surviving the Valley of Death in Women’s Health – with Patric Stenberg (Gesynta Pharma), Valentina Milanova (Daye), Amber Vodegel (28x)
  • The Women’s Health Label – Gift or Curse? · Live Debate – with Juan Camilo Arjona Ferreira (organon), Marissa Fayer (DeepLook Medical), Christian Lautner (Heal Capital), Annie Theriault (CBIV), Ida Tin (Clue)
  • Passport to Scale: Taking Your Women’s Health Business Global – with Vanessa Carpenter (Femtech Across Borders), Annie Theriault (CBIV), Victorine Lançon (Daya Ventures), Dr Mridula Pore (Peppy)

Early bird pricing (ends 11 September):

Ticket typeEarly birdStandard
Startups, Scaleups, Investors, Non-Profits, Government£599 + VAT£699 + VAT
Corporates, Payors & Providers£1,799 + VAT£1,999 + VAT
Service Providers & Consultants£3,299 + VAT£3,499 + VAT

Register for Women’s Health Week Europe | See the full agenda for WHW

Women’s Sport Summit Europe 2026

6 October | Emirates Stadium, London

The first-ever Women’s Sport Summit expands W Group’s expertise in connecting key decision-makers to the sports industry.

WSS brings together rights holders, brands, investors, athletes, and media to accelerate commercial growth across the sector.

Agenda highlights include:

  • From capital to crowd: the women’s sport cycle at scale – with Omar Shaikh (Arsenal FC), Nicole McWilliams (Google), Kerstin Lutz (Mercury13), Jo Currie (BBC Sport)
  • Women’s sport through the investor lens: what gets funded – and why – Hugo Sever (APEX Capital)
  • Rethinking ROI: what are we measuring that doesn’t actually matter? – Fi Watherston (Metro Bank), Silvia Keiser (Billie Jean King Cup), Gabriel Akin-Odujobi (Crux Football), Tammy Parlour (WST)
  • Beyond the 90 minutes: matchday as a commercial product, not just a fixture – Maggie Murphy (Aston Villa Women FC), Sam Feasey (Diageo/Guinness), Molly Miller (OneFootball), Megan Feringa (The Athletic/The New York Times)

Early bird pricing (ends 11 September):

Ticket typeEarly birdStandard
General Pass£299 + VAT£399 + VAT
Service Providers & Consultants£1,799 + VAT£1,999 + VAT

Register for Women’s Sport Summit Europe | See the full agenda for WSS

Attending both events?

For group tickets or to attend both summits this October, contact Callum, W Group’s Client Success Lead, at [email protected].

Continue Reading

Entrepreneur

KOVE Medical raises €1.7 million to improve safety of foetal surgery

Published

on

KOVE Medical has raised €1.7 million to support first-in-human studies of an implantable device designed to reduce preterm birth risk after foetal surgery.

The University of Zurich spin-off is developing a device designed to close defects left by surgical instruments following fetoscopy, a minimally invasive procedure performed inside the womb.

Fetoscopies can treat life-threatening conditions before birth but require surgical instruments to pass through the uterine wall and amniotic sac.

This can weaken the protective membrane, causing fluid leakage or rupture and often leading to preterm birth.

KOVE Medical said in a statement on LinkedIn: “This is a crucial step forward for our company, and we are incredibly grateful for the strong support and trust from our syndicate of visionary angel investors.”

KOVE Medical says its device closes the defect at the end of the procedure, stabilising the membrane and preventing complications. The aim is to make in-utero interventions safe enough to become a standard method of care.

The company plans to use the seed funding to reach first-in-human studies, a key milestone for a medical device seeking regulatory approval.

The CHF1.6m round was backed by a syndicate of angel investors.

Continue Reading

Events

WHIS 2026 adds 18 new speakers to October summit agenda

Published

on

The Women’s Health Innovation Summit (WHIS), the event uniting the global  women’s health ecosystem, has just announced 18 new speakers joining the agenda for  its 2026 summit, taking place October 13–15 at Encore Boston Harbor.

The latest additions bring further depth across pharma, clinical research, health  systems, venture, and policy, reinforcing WHIS’s role as the only platform where the full women’s health ecosystem convenes under one roof.

Newly confirmed speakers include:

  • Kelle Moley, MD – VP, Women’s Health Early Phase Clinical Development, Cardiometabolic Research, Eli Lilly & Company
  • Justine Levin-Allerhand – Executive Partner, Chief Corporate Development Officer & COO, Flagship Labs, Flagship Pioneering
  • Sebnem Yildirimoglu, MD, PMP – Executive Director, Women’s Health Strategy, Premier Research
  • Terri Stewart – Head of Global Healthcare & Government Affairs, EMD Serono
  • Dr. Morag Grassie – Executive Director, Blavatnik Fund for Innovation, Yale
  • Sandra Butler – Director, Design Impact, Mass General Brigham
  • Zhenya Lindgardt – Chief Executive Officer, Sera Prognostics
  • Sadie Morahan – Head of US Revenue, Withings Health Solutions
  • Angela Drew, PhD – Vice President, Regulatory Strategy, Premier Research
  • Dr. Stephanie Lahr – CMIO, Aqurio
  • Michelle Andrews – Contributing Writer, KFF Health News
  • Charlotte Williams – CEO, My Bump Hub
  • Clint Dart, MS – Director, NIH Women’s Health Data Coordinating Center, Premier Research
  • Cass Sanford – US Venture Advisor, FemTech Lab
  • Megan Mukuria – Founder & CEO, ZanaAfrica
  • Tiffany Inglis, MD, FACOG – Chief Medical Officer, Sera Prognostics
  • Angelean Hendrix, PhD – Vice President, Pharmacometrics and MIDD, Premier Research
  • Amanda Ducach – CEO & Co-founder, EmaEQ

“WHIS is where the women’s health industry comes together to take action,” said Poppy Howard-Wall, Event Director at WHIS.

“This latest wave of speakers reflects exactly the kind of cross-sector expertise our attendees expect – from global pharma and clinical research leadership to venture, health systems, and grassroots innovation.

“It’s this breadth that makes WHIS the room where things actually move forward.”

Bringing the Full Ecosystem Together

These additions join a growing 2026 agenda spanning four content tracks that reflect the  full lifecycle of healthcare innovation, from early-stage research and development  through to patient delivery, system transformation, and commercial scale.

Attendees can expect over 1,000 senior decision-makers, 120+ expert speakers, four dedicated stages, and more than 10 hours of curated 1:1 meetings.

Full speaker and agenda details are available at whisusa.com/speakers-2026.

About WHIS

The Women’s Health Innovation Summit is the only platform uniting the full women’s  health ecosystem – providers, payers, employers, pharma leaders, investors, and innovators -to increase deal flow, expand reimbursement, improve access, and deliver better outcomes for women at every stage of life.

 

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.